Enhancing Oncology Model: The blueprint for value-based care for specialists?
September 4th 2023"The EOM may facilitate success for its oncology participants by reducing reporting burdens, simplifying requirements, and offering potentially large bonus payments for lowering costs," writes Robert A. Dowling, MD.
Investment portfolio rebalancing is key to long-term success
September 1st 2023"Portfolio rebalancing is a necessary part of an effective investment strategy, and a routine check of your investments should be completed regularly to ensure they have not drifted too far from their intended percentage targets," writes Jeff Witz, CFP.
FDA grants priority review to enzalutamide for nonmetastatic HSPC
August 23rd 2023The application is specifically for use of enzalutamide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence and is supported by data from the phase 3 EMBARK trial.
Prostate cancer treatment deintensification: When less is more
August 16th 2023"Despite challenges, ongoing research and advancements in risk stratification, imaging techniques, and targeted therapies are paving the way for personalized and precision medicine approaches in prostate cancer management," writes Michael S. Cookson, MD, MMHC, FACS.
UGN-102 improves on current standard in low-grade intermediate-risk NMIBC
August 8th 2023The mitomycin-containing reverse thermal gel UGN-102 with or without TURBT reduced the risk of recurrence, progression, or death vs TURBT alone in patients with low-grade intermediate-risk non-muscle invasive bladder cancer.
Investigators assess applicants’ considerations in preference signaling for urology residency
July 25th 2023In total, 77.8% of Black respondents, 72.7% of Asian respondents, 57.1% of Latino respondents, and 46.5% of White respondents indicated that the racial and ethnic diversity of residents at a program influenced their decision to preference signal or sub-internship with that program.